| 词条 | Risankizumab |
| 释义 |
| type = mab | image = | alt = | mab_type = | source = zu | target = interleukin 23A | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_UK = | legal_US = | legal_UN = | legal_NZ = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = | CAS_number = 1612838-76-2 | ATC_prefix = L04 | ATC_suffix = AC18 | PubChem = | DrugBank = | C = 6476 | H = 9992 | N = 1720 | O = 2016 | S = 44 | molecular_weight = 145.6 kDa | UNII = 90ZX3Q3FR7 | KEGG = D11052 | synonyms = BI-655066 | ChemSpiderID = none }} Risankizumab also known as BI-655066 is a humanized monoclonal antibody targeting interleukin 23A (IL-23A).[1] Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. It is an experimental drug that has not been approved for the treatment of any medical conditions. The therapeutic potential of risankizumab was evaluated for the treatment of psoriasis in a preliminary phase 2 clinical trial. Clinical Drug Trial InformationPsoriasisIn a phase I clinical trial, thirty-nine patients received single-dose Risankizumab, 18 of which received the drug intravenously, 13 subcutaneously, and 8 received the placebo drug. There were several instances that adverse effects occurred but in the same frequency for the placebo and the experimental groups. Four serious adverse events occurred in the Risankizumab treated patients of which all were judged not treatment related, . Risankizumab was associated with clinical improvement in individuals treated with the drug, from week 2 and maintained for up to 66 weeks after treatment. At week 12 of treatment, 75%, 90%, and 100% decreases in the Psoriasis Area and Severity Index (PASI) were achieved by 87%, 58%, and 16% of Risankizumab treated patients, regardless of dose, respectively, versus individuals receiving placebo. Significant correlation between treatment-associated molecular changes and PASI improvement was observed in the Risankizumab treated patients.[2] The efficacy, safety and tolerability was further investigated in a phase III program comprising 4 clinical trials which compared Risankizumab to Ustekinumab, Adalimumab and Placebo in the indication of plaque psoriasis. The results of these trials confirmed the good efficicy and tolerability of Risankizumab. [3] A marketing authorization application for Risankizumab has been submitted to the US regulatory authority FDA, the European medicines agency (EMA) and other regulatory agencies. References1. ^{{cite journal|last1=Singh|first1=Sanjaya|title=Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody|journal=Mabs|date=July–August 2015|volume=7|issue=4|pages=778–791|doi=10.1080/19420862.2015.1032491|pmc=4622456}} [4]{{monoclonals for immune system}}2. ^Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015; 136(1): 116-124.e7 3. ^Gordon KB, Strober B, Lebwohl M, et al., Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 Aug 25;392(10148):650-661 4. ^{{cite web|title=Risankizumab|url=http://drugspider.com/drug/risankizumab|website=Drug Spider|accessdate=May 26, 2016}} 2 : Clinical trials|Monoclonal antibodies |
| 随便看 |
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。